| Date Filed | Type | Description |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/27/2023 |
4
| Wadhane Jitendra (Chief Accounting Officer) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Bought 2,500 shares
@ $1.87, valued at
$4.7k
|
|
| 09/27/2023 |
4
| Connealy Pamela Ann (CFO and COO) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Bought 6,426 shares
@ $1.8468, valued at
$11.9k
|
|
| 09/26/2023 |
4
| Dupont Jakob (Director) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 392,461 options to buy
@ $1.6, valued at
$627.9k
|
|
| 08/25/2023 |
4
| Dupont Jakob (Director) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 5,879 options to buy
@ $26.61, valued at
$156.4k
Granted 3,534 options to buy
@ $26.61, valued at
$94k
Granted 17,250 options to buy
@ $15.37, valued at
$265.1k
|
|
| 08/25/2023 |
3
| Dupont Jakob (Director) has filed a Form 3 on Pyxis Oncology, Inc. |
| 08/25/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/23/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/23/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/23/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin...|
Docs:
|
"Pyxis Oncology Successfully Completes Acquisition of Apexigen August 23, 2023 Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 Guidance on development strategy, timelines and milestones for the newly acquired Phase 2 sotigalimab CD40 agonist to be shared in 4Q23 BOSTON, Aug. 23, 2023 -- Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the successful c..." |
|
| 08/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The Merger On May 23, 2023, Pyxis Oncology, Inc., a Delaware corporation , entered into an Agreement and Plan of Merger , by and among the Company, Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of the Company , and Apexigen, Inc., a Delaware corporation , pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will merge with and into Apexigen , with Apexigen surviving such Merger as a wholly-owned subsidiary of the Company. Definitions for the capitalized terms used in this section are provided herein. Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger : a) Each share of common stock, par value $0.0001 per share, of..." |
|
| 08/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/28/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
| 07/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/30/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/30/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/29/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/08/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/25/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
|